A series of clinical trials combining CTLA-4 and PD-1/PD-L1 blockades for the treatment of HNSCC confirmed the superiority of the combinatorial therapy vs. monotherapy (Table 1). The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.